Abstract
Polycystic Ovary Syndrome (PCOS) is a leading cause of infertility, characterized by hormonal imbalances and ovulatory dysfunction. While letrozole is the current standard for ovulation induction, its impact on live birth rates and pregnancy complications remains a subject of investigation. Acupuncture is a frequently sought alternative, yet clinical trials have often utilized "fixed" protocols that do not account for the individualization central to Traditional Chinese Medicine (TCM). This protocol describes a large-scale, multicenter randomized controlled trial (RCT) designed to evaluate whether personalized acupuncture, based on TCM syndrome differentiation, improves live birth rates compared to fixed acupuncture, letrozole, or placebo.
Introduction
Infertility in women with PCOS is a complex clinical challenge. Letrozole, a selective aromatase inhibitor, is the first-line pharmaceutical intervention for inducing ovulation. However, it does not necessarily address the broader metabolic and hormonal environment that influences miscarriage rates and pregnancy complications.
Traditional Chinese Medicine (TCM) posits that effective treatment requires "syndrome differentiation"—tailoring needle points and techniques to a patient's specific constitution and symptoms. Previous acupuncture trials for PCOS have yielded conflicting results, potentially because they employed standardized, "fixed" protocols for all participants. This study addresses a fundamental question: Does personalizing acupuncture according to TCM principles make it a viable clinical alternative or adjunct to pharmaceutical intervention?
Methods and Study Design
This study is a randomized, assessor-blinded, multicenter trial involving 1,100 women across 28 hospitals in China. Participants are women aged 20–40 diagnosed with PCOS-related infertility.
Intervention Arms
Participants are randomly assigned to one of four groups for a 16-week treatment period:
- Personalized Acupuncture: Treatment is tailored to specific TCM syndromes (e.g., Spleen-yang and kidney-yang deficiency). This includes specific needle points, manual manipulation, and moxibustion.
- Fixed Acupuncture: A standardized set of acupuncture points is used for all patients, regardless of individual TCM diagnosis.
- Letrozole: Participants receive 2.5 mg to 7.5 mg of letrozole daily for five days per cycle.
- Placebo Letrozole: An inactive pill serves as the control group.
Hypotheses and Expected Outcomes
The researchers hypothesize a hierarchy of effectiveness for the primary outcome of live birth rate: Letrozole > Personalized Acupuncture > Fixed Acupuncture > Placebo.
Beyond simple ovulation induction, the study aims to determine if personalized acupuncture is superior at "preparing the soil"—improving the metabolic and hormonal environment to reduce pregnancy loss and complications. Secondary outcomes include:
- Ovulation and conception rates.
- Changes in hormonal parameters (testosterone, FSH, LH).
- Metabolic changes and quality-of-life scores (SF-36, PCOS-QOL).
Discussion and Significance
This trial represents the first multicenter RCT to rigorously compare personalized acupuncture against both pharmaceutical standards and fixed-protocol acupuncture. By mapping subjective TCM diagnoses onto repeatable, standardized acupuncture protocols, the study bridges the gap between holistic medicine and clinical rigor. If the results demonstrate that personalized acupuncture significantly outperforms fixed protocols, it will provide a strong evidence base for integrating individualized TCM strategies into modern reproductive medicine.
Summary updated